This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Incyte (INCY) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Incyte's (INCY) second-quarter 2023 earnings are likely to have gained from higher Jakafi sales and incremental sales from newly approved drugs.
AZNPositive Net Change NVSPositive Net Change INCYNegative Net Change ACADPositive Net Change
biotechnology earnings medical
Biotech Stock Roundup: BIIB, GSK's Q2 Earnings, KOD Faces Setback & More
by Zacks Equity Research
Earnings updates from Biogen (BIIB) and GSK (GSK) are in focus in the biotech sector.
GSKPositive Net Change BIIBPositive Net Change GILDPositive Net Change KODPositive Net Change
biotechnology biotechs pharmaceuticals
Visteon (VC)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
VCPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Dana (DAN) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
DANPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Par Petroleum (PARR)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
PARRNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Aquestive (AQST) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Aquestive's (AQST) second-quarter 2023 revenues are likely to have been driven by rising licensed product revenues.
AZNPositive Net Change ACADPositive Net Change ASRTNegative Net Change AQSTPositive Net Change
biotechnology earnings medical
Bristol-Myers (BMY) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Investors are likely to focus on the demand for Eliquis and Opdivo along with an incremental contribution from newer drugs when Bristol-Myers (BMY) reports Q2 results.
AZNPositive Net Change GSKPositive Net Change BMYPositive Net Change NVONegative Net Change
biotechnology earnings
Kodiak (KOD) Down as Late-Stage DME Studies Fail
by Zacks Equity Research
Kodiak (KOD) stock plunges as it failed to meet the primary endpoint in phase III studies evaluating tarcocimab in diabetic macular edema patients.
ADCTPositive Net Change ACADPositive Net Change KODPositive Net Change
biotechnology medical
Gilead (GILD) Ends Myelodysplastic Syndromes Study on Magrolimab
by Zacks Equity Research
Gilead Sciences, Inc. (GILD) discontinues phase III ENHANCE study, evaluating the potential of magrolimab as a treatment for higher-risk myelodysplastic syndromes, due to futility based on a planned analysis.
ALKSNegative Net Change GILDPositive Net Change ANIXNegative Net Change ACLXPositive Net Change
biotechnology biotechs
Roche (RHHBY) SMA Drug Gets Positive CHMP Opinion for Expanded Use
by Zacks Equity Research
Roche's (RHHBY) Evrysdi gets a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for extended use in infants under two months with spinal muscular atrophy.
RHHBYPositive Net Change ADCTPositive Net Change ACADPositive Net Change
biotechnology medical
Vir Biotechnology (VIR) Down on Influenza Study Failure
by Zacks Equity Research
Vir Biotechnology (VIR) crashes after the phase II study evaluating VIR-2482 for preventing symptomatic influenza A illness fails to meet goals.
GSKPositive Net Change ALKSNegative Net Change ANIXNegative Net Change VIRPositive Net Change
biotechnology biotechs
Biotech Stock Roundup: BBIO, ARGX Soar on Study Results, APLS Down on Safety Issues
by Zacks Equity Research
Regulatory and key pipeline updates from BridgeBio (BBIO) and argenx (ARGX) are in focus in the biotech sector.
ARGXPositive Net Change APLSPositive Net Change BBIOPositive Net Change VIRPositive Net Change
biotechnology pharmaceuticals
Greif (GEF)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
GEFNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Alkermes (ALKS) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Higher sales of Alkermes' (ALKS) key drugs like Vivitrol, Aristada and Lybalvi are likely to have driven second-quarter sales.
JNJNegative Net Change ALKSNegative Net Change ADCTPositive Net Change ACADPositive Net Change
biotechnology earnings medical
Emergent's (EBS) Cyfendus Anthrax Vaccine Gets FDA Nod
by Zacks Equity Research
Emergent's (EBS) shares rise as its anthrax vaccine, Cyfendus (AV7909), gets FDA approval, offering preventive measures for people aged 18 to 65, who were exposed to the harmful bacillus anthracis germ.
ADCTPositive Net Change EBSNegative Net Change ACADPositive Net Change
biotechnology medical
Bear of the Day: Ligand Pharmaceuticals (LGND)
by Kevin Cook
Ligand is an innovative Bio-Pharma M&A royalty-generator, but the model is volatile
LGNDPositive Net Change
biotechnology pharmaceuticals
Recursion (RXRX) Stock Surges 191% in 3 Months: Here's Why
by Zacks Equity Research
Recursion's (RXRX) shares rallied almost 191% over the past three months, owing to artificial intelligence-driven acquisitions and strategic collaborations to advance drug development.
ALKSNegative Net Change NVDAPositive Net Change RXRXNo Net Change
biotechnology medical
Apellis (APLS) Plunges on Safety Issues With Eye Treatment
by Zacks Equity Research
Apellis (APLS) suffers a setback on reports of six events of retinal vasculitis (or inflammation) following treatment with Syfovre (pegcetacoplan injection).
ALKSNegative Net Change APLSPositive Net Change ANIXNegative Net Change
biotechnology biotechs
Pieris (PIRS) Pursues Strategic Alternatives, Stock Rises
by Zacks Equity Research
Pieris (PIRS) announces strategic update after partner AstraZeneca terminated collaboration agreement and returned the rights to elarekibep.
AZNPositive Net Change ALKSNegative Net Change PIRSPositive Net Change
biotechnology medical
Should You Buy Moelis (MC) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
MCPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy Agios Pharmaceuticals (AGIO) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
AGIOPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
BridgeBio (BBIO) Up as Heart Drug Meets Primary Goal in Study
by Zacks Equity Research
BridgeBio's (BBIO) shares surge on announcing positive data from a late-stage study evaluating acoramidis for patients with transthyretin amyloid cardiomyopathy.
ALNYPositive Net Change ALKSNegative Net Change BBIOPositive Net Change
biotechnology medical
Corcept's (CORT) Early-Stage Study on NASH Reveals Positive Data
by Zacks Equity Research
Corcept's (CORT) early-stage candidate miricorilant, evaluated to treat patients with presumed non-alcoholic steatohepatitis, shows encouraging data.
ALKSNegative Net Change CORTPositive Net Change ICPTPositive Net Change
biotechnology medical
Gilead's (GILD) Veklury Gets FDA Nod for Label Expansion
by Zacks Equity Research
Gilead's (GILD) antiviral treatment Veklury (remdesivir) has now been approved for the treatment of COVID-19 patients with severe renal impairment, including those on dialysis.
ALKSNegative Net Change GILDPositive Net Change LGNDPositive Net Change
biotechnology biotechs pharmaceuticals
Apellis (APLS) Stock Surges 62% in 6 Months: Here's Why
by Zacks Equity Research
Apellis' (APLS) shares have rallied 62% over the past six months due to the approval of Syfovre (pegcetacoplan injection) in February. An encouraging uptake of its first marketed product, Empaveli, has further bolstered the stock value.
IMGNPositive Net Change APLSPositive Net Change AKROPositive Net Change
biotechnology medical